XBIO

Xenetic Biosciences Stock Price

2.22
-0.02 (-0.89%)
2.22

Low
0.76

52 Week Range

High
5.68

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Xenetic Biosciences Inc XBIO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.02 -0.89% 2.22 16:34:56
Open Price Low Price High Price Close Price Prev Close
2.27 2.19 2.28 2.22 2.24
Bid Price Ask Price Spread News
2.21 2.26 0.05 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
934 297,437 $ 2.24 $ 666,720 - 0.76 - 5.68
Last Trade Time Type Quantity Stock Price Currency
16:17:22 formt 158 $ 2.21 USD

Period:

Draw Mode:

Xenetic Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 13.98M 6.30M 422.99k $ 436.94k $ - -9.62 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 1.00 12.20%

more financials information »

Xenetic Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical XBIO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.342.422.172.28414,384-0.12-5.13%
1 Month3.123.15952.172.65529,747-0.90-28.85%
3 Months1.995.681.653.1211,067,3190.2311.56%
6 Months2.515.681.503.105,105,910-0.29-11.55%
1 Year0.91185.680.763.012,860,5441.31143.47%
3 Years3.6016.88950.442.751,169,893-1.38-38.33%
5 Years3.7516.88950.442.85764,152-1.53-40.8%

Xenetic Biosciences Description

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer.


Your Recent History
NASDAQ
XBIO
Xenetic Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.